A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection.

The Th1/Th2 cytokine balance is important in persistence of infection and liver injury in chronic hepatitis C. The aim of this study was to administer the anti-inflammatory cytokine, recombinant human interleukin-10 (rHuIL-10), for 28 days in patients with chronic hepatitis C and to assess the safety and measure the effect on alanine aminotransferase (ALT, a marker of hepatic inflammation) levels and serum hepatitis C virus (HCV) RNA values. Three treatment-naive and 13 interferon (IFN) nonresponder patients (total 16 patients) with compensated chronic HCV infection were enrolled in this study. Patients were randomized to receive rHuIL-10 at a dose of 4 or 8 microg/kg/day as a single daily subcutaneous injection for 28 days. ALT values and serum HCV RNA were measured at days 0, 1, 3, 8, 15, 22, and 28 during therapy and at follow-up 2 and 4 weeks after cessation of the 4-week treatment period. ALT values normalized in 9 of 16 patients during therapy and remained normal until the end of treatment in 8 patients. The decreases in ALT values occurred in both the 4 microg and 8 microg dosage groups and were seen in both IFN naive and nonresponder patients. Mean ALT values fell significantly during the study period but usually returned to pretreatment levels by the end of the 4-week follow-up period (p < 0.05). HCV RNA concentrations did not vary significantly during or after therapy. (No patient had either an increase or a decrease in HCV RNA levels of > or =1.5 log during the study.) The drug was well tolerated, with no adverse symptoms noted. Platelet counts fell transiently to 73,000 and 63,000 in 2 patients. No other toxicity was observed, and no patients discontinued therapy. In chronic hepatitis C, short-term therapy with IL-10 was well tolerated and caused transient normalization of ALT values in 50% of patients, which returned to pretreatment levels on cessation of treatment. There were no significant changes observed in serum HCV RNA concentrations during the study. These immunomodulatory effects are similar to those observed with ribavirin monotherapy in chronic hepatitis C. Further study of rHuIL-10 alone or in combination with antiviral agents in chronic hepatitis C is warranted.

[1]  P. Marcellin,et al.  Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon- Therapy , 1997, Annals of Internal Medicine.

[2]  M. Reding.  Recent developments in hepatitis C antiviral research 1999 - 2000 , 2000 .

[3]  T. Mosmann,et al.  IL-10 inhibits cytokine production by activated macrophages. , 1991, Journal of immunology.

[4]  J. McHutchison,et al.  Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison , 1997, Hepatology.

[5]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[6]  R. Adkins,et al.  Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. , 1994, Gastroenterology.

[7]  Eugene R. Schiff,et al.  National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C , 1997, Hepatology.

[8]  Edoardo Cervoni,et al.  Hepatitis C , 1998, The Lancet.

[9]  M. Peters,et al.  Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. , 1988, Annals of internal medicine.

[10]  S. Issa,et al.  Liver transplantation for chronic viral hepatitis. , 1999, The Surgical clinics of North America.

[11]  T. Mosmann.  Properties and functions of interleukin-10. , 1994, Advances in immunology.

[12]  S. Govindarajan,et al.  Improved detection of hepatitis c virus antibodies in high‐risk populations , 1992, Hepatology.

[13]  K. Asadullah,et al.  Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. , 1999, Archives of dermatology.

[14]  B. Gao,et al.  IL‐10 attenuates IFN‐α‐activated STAT1 in the liver: involvement of SOCS2 and SOCS3 , 2000 .

[15]  E. Keystone,et al.  IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. , 1998, Rheumatic diseases clinics of North America.

[16]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[17]  E. Radwanski,et al.  Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. , 1996, Blood.

[18]  Hassan Mohammad Naif,et al.  The inhibition of HIV replication in monocytes by interleukin 10 is linked to inhibition of cell differentiation. , 1996, AIDS research and human retroviruses.

[19]  C. Elson,et al.  Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. , 1997, Gastroenterology.

[20]  T. Mondala,et al.  Fluctations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection , 1996 .

[21]  L. Stuyver,et al.  Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. , 1993, The Journal of general virology.

[22]  E. Holmes,et al.  A proposed system for the nomenclature of hepatitis C viral genotypes , 1994, Hepatology.

[23]  H. Tsukamoto.  Is interleukin‐10 antifibrogenic in chronic liver injury? , 1998, Hepatology.

[24]  P. Huie,et al.  Interferon-gamma and interleukin-10 messenger RNA are up-regulated after orthotopic liver transplantation in tolerant rats: evidence for cytokine-mediated immune dysregulation. , 1995, Surgery.

[25]  W Sterry,et al.  IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. , 1998, The Journal of clinical investigation.

[26]  M. Alter,et al.  Epidemiology of Hepatitis C , 2018, Clinical liver disease.

[27]  H. Thomas,et al.  A phase I/II study of recombinant human interleukin‐12 in patients with chronic hepatitis C , 1999, Hepatology.

[28]  T. Poynard,et al.  Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration , 1996, Hepatology.

[29]  Wei Wu,et al.  Interleukin‐10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice , 1998, Hepatology.

[30]  G. Gerken,et al.  Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. , 1995, Journal of hepatology.

[31]  J. Hoofnagle,et al.  10‐year follow‐up after interferon‐α therapy for chronic hepatitis C , 1998 .

[32]  P. Marcellin,et al.  A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. , 2000, Journal of hepatology.

[33]  Hassan Mohammad Naif,et al.  Inhibition of human immunodeficiency virus replication in differentiating monocytes by interleukin 10 occurs in parallel with inhibition of cellular RNA expression. , 1996, AIDS research and human retroviruses.

[34]  G. Bishop,et al.  Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1‐associated cytokines , 1996, Hepatology.

[35]  L. Shapiro,et al.  A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. , 1995, Journal of immunology.

[36]  O. Weiland,et al.  The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. , 1998, The Journal of general virology.

[37]  M. Koffler.  Epidemiology of hepatitis. , 1965, Lancet.

[38]  J. Fallowfield,et al.  Interleukin‐10 expression and function in experimental murine liver inflammation and fibrosis , 1998, Hepatology.